We are delighted at the news that the CAR T-cell therapy tisagenlecleucel (Kymriah®) has been recommended for use on the NHS in Scotland for adults with diffuse large B-cell lymphoma (DLBCL) that has not responded (refractory) or has come back (relapsed) after two or more previous treatments.
In March, we reported on the disappointing initial decision of the Scottish Medicines Consortium (SMC) not to recommend CAR T-cell therapy in Scotland. The SMC originally stated that there was not enough evidence to be certain that the health benefits of tisagenlecleucel for people with relapsed or refractory DLBCL outweigh its costs. The treatment has since been reassessed and Lymphoma Action was among the patient representative organisations who submitted a response stressing the potential benefits of CAR T-cell therapy for people with otherwise very limited treatment options. The SMC’s decision takes account of a Patient Access Scheme that improves the cost-effectiveness of tisagenlecleucel. Novartis, the company that manufactures tisagenlecleucel, applied a confidential discount to the cost of the medicine.
CAR T-cell therapy is already available on the NHS in England and Wales and we are pleased that the SMC’s decision ensures equality of access to this potentially life-saving treatment across the UK.
9 September 2019